|
1
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: Rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick H, Sultan C and Cox C: The chronic
myeloid leukaemias: Guidelines for distinguishing chronic
granulocytic, atypical chronic myeloid, and chronic myelomonocytic
leukaemia. Proposals by the French-American-British cooperative
leukaemia group. Br J Haematol. 87:746–754. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Germing U, Strupp C, Knipp S, Kuendgen A,
Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N and
Bennett JM: Chronic myelomonocytic leukemia in the light of the WHO
proposals. Haematologica. 92:974–977. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zandberg DP, Huang TY, Ke X, Baer MR, Gore
SD, Smith SW and Davidoff AJ: Treatment and outcomes for chronic
myelomonocytic leukemia compared to myelodysplastic syndromes in
older adults. Haematologica. 98:584–590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wassie EA, Itzykson R, Lasho TL, Kosmider
O, Finke CM, Hanson CA, Ketterling RP, Solary E, Tefferi A and
Patnaik MM: Molecular and prognostic correlates of cytogenetic
abnormalities in chronic myelomonocytic leukemia: A Mayo
clinic-french consortium study. Am J Hematol. 89:1111–1115. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patnaik MM and Tefferi A: Cytogenetic and
molecular abnormalities in chronic myelomonocytic leukemia. Blood
Cancer J. 6:e3932016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benton CB, Nazha A, Pemmaraju N and
Garcia-Manero G: Chronic myelomonocytic leukemia: Forefront of the
field in 2015. Crit Rev Oncol Hematol. 95:222–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elena C, Galli A, Such E, Meggendorfer M,
Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, et
al: Integrating clinical features and genetic lesions in the risk
assessment of patients with chronic myelomonocytic leukemia. Blood.
128:1408–1417. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheson BD, Greenberg PL, Bennett JM,
Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM,
Stone RM, et al: Clinical application and proposal for modification
of the International Working Group (IWG) response criteria in
myelodysplasia. Blood. 108:419–425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bennett JM, Andersen JW and Cassileth PA:
Long term survival in acute myeloid leukemia: The Eastern
Cooperative Oncology Group (ECOG) experience. Leuk Res. 15:223–227.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patnaik MM, Wassie EA, Lasho TL, Hanson
CA, Ketterling R and Tefferi A: Blast transformation in chronic
myelomonocytic leukemia: Risk factors, genetic features, survival,
and treatment outcome. Am J Hematol. 90:411–416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang G, Fu B, Hu S, Lu X, Tang Z, Li S,
Jabbar K, Khoury JD, Medeiros LJ and Wang SA: Prognostic impact of
acquisition of cytogenetic abnormalities during the course of
chronic myelomonocytic leukemia. Am J Hematol. 90:882–887. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patnaik MM and Tefferi A: Chronic
myelomonocytic leukemia: 2016 update on diagnosis, risk
stratification, and management. Am J Hematol. 91:631–642. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Itzykson R, Kosmider O, Renneville A,
Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L,
Fenaux P, Beyne-Rauzy O, Vey N, et al: Prognostic score including
gene mutations in chronic myelomonocytic leukemia. J Clin Oncol.
31:2428–2436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S,
Patel A, Goswami M, Khoury JD, Garcia-Manero G, et al: Cytogenetic
risk stratification of 417 patients with chronic myelomonocytic
leukemia from a single institution. Am J Hematol. 89:813–818. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calvo X, Nomdedeu M, Santacruz R, Martinez
N, Costa D, Pereira A, Estrada N, Xicoy B, Esteve J and Nomdedeu B:
Comparison of three prognostic scoring systems in a series of 146
cases of chronic myelomonocytic leukemia (CMML): MD Anderson
prognostic score (MDAPS), CMML-specific prognostic scoring system
(CPSS) and Mayo prognostic model. A detailed review of prognostic
factors in CMML. Leuk Res: S0145-2126(15)30324-6. 2015. View Article : Google Scholar
|
|
19
|
Such E, Cervera J, Costa D, Solé F,
Vallespí T, Luño E, Collado R, Calasanz MJ, Hernández-Rivas JM,
Cigudosa JC, et al: Cytogenetic risk stratification in chronic
myelomonocytic leukemia. Haematologica. 96:375–383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Patnaik MM, Itzykson R, Lasho TL, Kosmider
O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A and
Solary E: ASXL1 and SETBP1 mutations and their prognostic
contribution in chronic myelomonocytic leukemia: A two-center study
of 466 patients. Leukemia. 28:2206–2212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patnaik MM, Barraco D, Lasho TL, Finke CM,
Hanson CA, Ketterling RP, Gangat N and Tefferi A: DNMT3A mutations
are associated with inferior overall and leukemia-free survival in
chronic myelomonocytic leukemia. Am J Hematol. 92:56–61. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jaiswal S, Fontanillas P, Flannick J,
Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N,
Chavez A, et al: Age-related clonal hematopoiesis associated with
adverse outcomes. N Engl J Med. 371:2488–2498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jankowska AM, Makishima H, Tiu RV, Szpurka
H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C,
et al: Mutational spectrum analysis of chronic myelomonocytic
leukemia includes genes associated with epigenetic regulation: UTX,
EZH2, and DNMT3A. Blood. 118:3932–3941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kosmider O, Gelsi-Boyer V, Ciudad M,
Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN,
Beyne-Rauzy O, et al: TET2 gene mutation is a frequent and adverse
event in chronic myelomonocytic leukemia. Haematologica.
94:1676–1681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Patnaik MM, Lasho TL, Vijayvargiya P,
Finke CM, Hanson CA, Ketterling RP, Gangat N and Tefferi A:
Prognostic interaction between ASXL1 and TET2 mutations in chronic
myelomonocytic leukemia. Blood Cancer J. 6:e3852016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bejar R, Lord A, Stevenson K, Bar-Natan M,
Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G,
et al: TET2 mutations predict response to hypomethylating agents in
myelodysplastic syndrome patients. Blood. 124:2705–2712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eissa H, Gooley TA, Sorror ML, Nguyen F,
Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP, et al:
Allogeneic hematopoietic cell transplantation for chronic
myelomonocytic leukemia: Relapse-free survival is determined by
karyotype and comorbidities. Biol Blood Marrow Transplant.
17:908–915. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aribi A, Borthakur G, Ravandi F, Shan J,
Davisson J, Cortes J and Kantarjian H: Activity of decitabine, a
hypomethylating agent, in chronic myelomonocytic leukemia. Cancer.
109:713–717. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Courville EL, Wu Y, Kourda J, Roth CG,
Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A and
Hasserjian RP: Clinicopathologic analysis of acute myeloid leukemia
arising from chronic myelomonocytic leukemia. Mod Pathol.
26:751–761. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wijermans PW, Rüter B, Baer MR, Slack JL,
Saba HI and Lübbert M: Efficacy of decitabine in the treatment of
patients with chronic myelomonocytic leukemia (CMML). Leuk Res.
32:587–591. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Damaj G, Duhamel A, Robin M, Beguin Y,
Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh
J, et al: Impact of azacitidine before allogeneic stem-cell
transplantation for myelodysplastic syndromes: A study by the
Société Française de Greffe de Moelle et de Thérapie-Cellulaire and
the Groupe-Francophone des Myélodysplasies. J Clin Oncol.
30:4533–4540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kantarjian HM, O'Brien S, Huang X,
Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J,
Bueso-Ramos CE and Issa JP: Survival advantage with decitabine
versus intensive chemotherapy in patients with higher risk
myelodysplastic syndrome: Comparison with historical experience.
Cancer. 109:1133–1137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Duchmann M, Braun T, Micol JB, Platzbecker
U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, et
al: Validation of response assessment according to international
consortium for MDS/MPN criteria in chronic myelomonocytic leukemia
treated with hypomethylating agents. Blood Cancer J. 7:e5622017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng Q, Li JY, Liu PJ and Zhao MF:
Successful management of acute myeloid leukemia transformed from
chronic myelomonocytic leukemia in the elderly by a combination
regimen of decitabine and cytarabine, aclarubicin and granulocyte
colony-stimulating factor: A case report. Oncol Lett. 9:1217–1220.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Padron E, Dezern A, Andrade-Campos M,
Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan
H, et al: A multi-institution phase I trial of ruxolitinib in
patients with chronic myelomonocytic leukemia (CMML). Clin Cancer
Res. 22:3746–3754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Padron E, Painter JS, Kunigal S, Mailloux
AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton
G, et al: GM-CSF-dependent pSTAT5 sensitivity is a feature with
therapeutic potential in chronic myelomonocytic leukemia. Blood.
121:5068–5077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Komrokji RS, Seymour JF, Roberts AW,
Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, et
al: Results of a phase 2 study of pacritinib (SB1518), a
JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood.
125:2649–2655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Emanuel PD, Bates LJ, Castleberry RP,
Gualtieri RJ and Zuckerman KS: Selective hypersensitivity to
granulocyte-macrophage colony-stimulating factor by juvenile
chronic myeloid leukemia hematopoietic progenitors. Blood.
77:925–929. 1991.PubMed/NCBI
|
|
39
|
Savona MR, Malcovati L, Komrokji R, Tiu
RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R,
et al: An international consortium proposal of uniform response
criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
in adults. Blood. 125:1857–1865. 2015. View Article : Google Scholar : PubMed/NCBI
|
